Last update April 16, 2024

ホシノプリルナトリウム

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Fosinopril and its active metabolite fosinoprilat are angiotensin converting enzyme inhibitors (ACEI) used in the treatment of hypertension and heart failure. Oral administration once day.

Except for a reference of the manufacturer (FDA 2002) with no declared values, since the last update we have not found published data on its excretion in breastmilk.

Other compounds in the same group (ACEI) are not significantly excreted in breast milk, but until further published data on this drug in relation to breastfeeding are known safer alternatives may be preferable. (Hale, LactMed, Anderson 2018)

Due to its potential renal toxicity in premature infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015)

The protective role of breastfeeding against maternal hypertension has been proven. (Park 2018)

 

Alternatives

  • Captopril ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

ホシノプリルナトリウム is Fosinopril sodium in Japanese.

Is written in other languages:

Groups

ホシノプリルナトリウム belongs to these groups or families:

Tradenames

Main tradenames from several countries containing ホシノプリルナトリウム in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 36 %
Molecular weight 586 daltons
Protein Binding 95 %
pKa 3.78 -
Tmax 3 hours
14 hours

References

  1. Anderson PO. Treating Hypertension During Breastfeeding. Breastfeed Med. 2018 Abstract
  2. Park S, Choi NK. Breastfeeding and Maternal Hypertension. Am J Hypertens. 2018 Abstract
  3. AEMPS. Fosinopril. Ficha técnica. 2017 Full text (in our servers)
  4. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract
  5. FDA (Bristol-M-S). Fosinopril. Drug Summary. 2002 Full text (in our servers)

Total visits

1,338

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM